Endonovo Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENDV research report →
Price Chart
About the company
Endonovo Therapeutics, Inc. , a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology.
- CEO
- Alan Brian Collier
- IPO
- 2012
- Employees
- 1
- HQ
- Woodland Hills, CA, US
Get TickerSpark's AI analysis on ENDV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.94K
- P/E
- -0.10
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -6.87
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 7.75%
- ROIC
- 4.46%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-945,766
- Net Income
- $-2,176,130+22.2%
- EPS
- $-0.00+60.8%
- OCF Growth
- -142.8%
- FCF Growth
- -142.8%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -8.04
- RSI (14)
- 46
- Avg Volume
- 383.99K
No earnings-call transcripts are available for ENDV yet.
- Free Float
- 75.3%
- Shares Outstanding
- 318.75M
- Float Shares
- 240.02M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 20 | Collier Alan Brian | buy | 100 |
| Jul 1, 20 | Collier Alan Brian | buy | 100 |
| Jun 30, 20 | Collier Alan Brian | buy | 200 |
| Feb 22, 20 | Collier Alan Brian | buy | 100 |
| Jan 2, 20 | Collier Alan Brian | buy | 100 |
| Dec 30, 19 | Collier Alan Brian | buy | 100 |
| Dec 16, 19 | Collier Alan Brian | buy | 500 |
| Dec 12, 19 | Collier Alan Brian | buy | 1,000 |
| Dec 11, 19 | Collier Alan Brian | buy | 100 |
| Dec 11, 19 | Collier Alan Brian | buy | 1,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENDV coverage
Recent articles, reports, and earnings notes.
No research on ENDV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENDV report →Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
globenewswire.com · Mar 28
Endonovo's SofPulse® to Be Featured at Innovative Pain Management Solutions
globenewswire.com · Mar 4
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
globenewswire.com · Dec 4
Endonovo's SofPulse® Secures Taiwan FDA Approval
globenewswire.com · Oct 12
Endonovo's SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
globenewswire.com · Aug 22
Endonovo's Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
globenewswire.com · Aug 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.